Zydus Lifesciences Ltd.

Cadila Healthcare is seeking shareholders’ nod for raising upto Rs 10,000 crore from the capital markets by issuing equity shares, including instruments such as convertible bonds/debentures through qualified institutional placement, to capitalise on the organic and inorganic growth opportunities available in the pharma sector.

While no specific instrument of securities were identified, the board might opt for an ‘appropriate instrument in the best interests of the company’. The resolution seeks approval of shareholders to offer equity shares in one or more tranches to investors, inter alia through QIP by way of private placement.

Cadila Healthcare operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.